Anna Morena D'Alise

14PUBLICATIONS
82CO-AUTHORS
Predictive and prognostic markersCancer geneticsMolecular targetsLiquid biopsiesInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|May 11, 2026
Mutations Targeted by Nous-209 Immunotherapy Occur Early in Lynch Syndrome Carriers' Precancer Lesions with Microsatellite Instability.

|Jan 16, 2026
Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial.

Anna Morena D'Alise, Jason Willis, Fahriye Duzagac

|Nov 30, 2025
Neoadjuvant personalized viral vaccine prevents tumor relapse in checkpoint-resistant murine melanoma model.

Laura Seclì, Linda Nocchi, Guido Leoni

|Nov 13, 2025
NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome.

Lorenzo De Marco, Elisa Micarelli, Joni Panula

|Mar 28, 2024
Development of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine.

Rosa Bartolomeo, Fulvia Troise, Simona Allocca

|Mar 20, 2024
Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses.

Anna Morena D'Alise, Guido Leoni, Gabriella Cotugno

Pageof 3

Frequent Collaborators

7 joint publications

Elisa Scarselli

5 joint publications

Guido Leoni

4 joint publications

Laura Seclì

4 joint publications

Elisa Micarelli